Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 18/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29564987 | 0.80 | HPGD (1.00) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL23675339 | 0.80 | HPGD (1.00) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL23680665 | 0.80 | HPGD (1.00) | HPGDALDH1A1SMN1; SMN2NPC1GLA | |
| SCHEMBL23680568 | 0.80 | HPGD (1.00) | HPGDALDH1A1SMN1; SMN2NPC1GLA | |
| SCHEMBL23675188 | 0.79 | HPGD (0.67) | HPGDALDH1A1SMN1; SMN2ADORA2ANPC1 | |
| SCHEMBL23680585 | 0.78 | HPGD (1.00) | HPGDALDH1A1SMN1; SMN2NPC1GLA | |
| SCHEMBL23680788 | 0.78 | HPGD (1.00) | HPGDALDH1A1SMN1; SMN2NPC1GLA | |
| SCHEMBL23675322 | 0.78 | HPGD (0.64) | HPGDALDH1A1NPC1RAB9A | |
| SCHEMBL28980715 | 0.77 | HPGD (0.61) | HPGDALDH1A1NPC1RAB9A | |
| SCHEMBL24328709 | 0.77 | HPGD (0.76) | HPGDALDH1A1SMN1; SMN2NPC1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115335043-B | PGDH inhibitors and methods of making and using the same | 迈欧伏特治疗公司 | 2025-03-28 | — | — | CN | disclosed |
| US-11891389-B2 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| CN-117377668-A | Inhalant formulations of PGDH inhibitors and methods of use thereof | 迈欧伏特治疗公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-4228650-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | Epirium Bio Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023009618-A1 | BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING | EPIRIUM BIO, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| EP-4093385-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | Myoforte Therapeutics Inc. (US) | 2022-11-30 | — | — | EP | disclosed |
| CN-115335043-A | PGDH inhibitors and methods of making and using | 迈欧伏特治疗公司 | 2022-11-11 | — | — | CN | disclosed |
| US-20220267325-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. | 2022-08-25 | — | — | US | disclosed |
| US-11345702-B1 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021151014-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
| WO-2021151014-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891389-B2 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | HPGD 1/4885ALDH1A1 145/4885SMN1; SMN2 4413/4885 |
| US-20220267325-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | HPGD, HPGDS, PTGS1 | HPGD 1/4885ALDH1A1 145/4885SMN1; SMN2 4413/4885 |
| US-11345702-B1 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | HPGD 1/4885ALDH1A1 145/4885SMN1; SMN2 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.